-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In multiple sclerosis (MS), the start or transition of treatment is usually determined based on the recurrence of the disease or the progression of disability.
Although immunomodulatory therapy can reduce disease activity, the time required for its optimal effect is currently unclear.
The purpose of this study is to develop a new method for determining how long MS treatment ("treatment lag") affects clinical disease activity.
The author of this study is Dr.
Izanne, and the results of the study will be announced at the 2021 American Academy of Neurology (AAN) annual meeting.
Author of this article: Yimaitong AAN report group Yimaitong compiled and compiled, please do not reprint without authorization.
Research Introduction The researchers conducted a retrospective analysis using MSBase from multinational MS registries and OFSEP data from French national registries.
The study subjects included patients diagnosed with MS, patients who received MS treatment for at least 1 year, patients who received at least 3 years of pre-treatment follow-up, and patients who were reviewed regularly every year.
In order to analyze the progress of disability, the researchers included all events in the following 5 years into the analysis.
Monte Carlo simulation is used to identify the first-order local minimum of the first-order derivative after the start of treatment.
This point is the point where the therapeutic effect is stable after the best treatment is observed.
Main findings: ➤Researchers included 11,180 eligible treatment period patients for recurrence analysis, and 4,088 treatment period patients for disability progression analysis.
These results are not significantly different from the verification analysis.
➤Researchers calculated the duration of recurrence delay for 10 treatments, ranging from 12 to 30 weeks; and the duration of treatment delay for 7 treatments for disability progression, ranging from 30 to 70 weeks.
Research conclusions This study has developed a new method and conducted external verification, which can objectively quantify the treatment lag duration of recurrence and disability progression in different treatments.
At the same time, this method will also be used in research to evaluate the impact of patient and disease characteristics on treatment delay.
Yimaitong compiled from: Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
AAN 2021.
Lock on the medlive-neurology channel (medlive-neurology), and check the latest information of AAN 2021 at the same time! Yimaitong AAN 2021 special report Long press the QR code to follow ☟☟☟ or click "Read the original text" to see more AAN 2021 topics related content!
Although immunomodulatory therapy can reduce disease activity, the time required for its optimal effect is currently unclear.
The purpose of this study is to develop a new method for determining how long MS treatment ("treatment lag") affects clinical disease activity.
The author of this study is Dr.
Izanne, and the results of the study will be announced at the 2021 American Academy of Neurology (AAN) annual meeting.
Author of this article: Yimaitong AAN report group Yimaitong compiled and compiled, please do not reprint without authorization.
Research Introduction The researchers conducted a retrospective analysis using MSBase from multinational MS registries and OFSEP data from French national registries.
The study subjects included patients diagnosed with MS, patients who received MS treatment for at least 1 year, patients who received at least 3 years of pre-treatment follow-up, and patients who were reviewed regularly every year.
In order to analyze the progress of disability, the researchers included all events in the following 5 years into the analysis.
Monte Carlo simulation is used to identify the first-order local minimum of the first-order derivative after the start of treatment.
This point is the point where the therapeutic effect is stable after the best treatment is observed.
Main findings: ➤Researchers included 11,180 eligible treatment period patients for recurrence analysis, and 4,088 treatment period patients for disability progression analysis.
These results are not significantly different from the verification analysis.
➤Researchers calculated the duration of recurrence delay for 10 treatments, ranging from 12 to 30 weeks; and the duration of treatment delay for 7 treatments for disability progression, ranging from 30 to 70 weeks.
Research conclusions This study has developed a new method and conducted external verification, which can objectively quantify the treatment lag duration of recurrence and disability progression in different treatments.
At the same time, this method will also be used in research to evaluate the impact of patient and disease characteristics on treatment delay.
Yimaitong compiled from: Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
AAN 2021.
Lock on the medlive-neurology channel (medlive-neurology), and check the latest information of AAN 2021 at the same time! Yimaitong AAN 2021 special report Long press the QR code to follow ☟☟☟ or click "Read the original text" to see more AAN 2021 topics related content!
